Paper430189
Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent.
Wieland DM and 3 others. J Nucl Med, 1979. Cited by 100 papers, by iCite.
Cite this record
ConductScience Library. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. Papers, record 430189. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/430189
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenal Medulla | Major topic |
| Bretylium Compounds | Major topic |
| Iodine Radioisotopes | Major topic |
| Animals | |
| Dogs | |
| Female | |
| Iodobenzenes | |
| Radionuclide Imaging | |
| Structure-Activity Relationship | |
| Tissue Distribution |
Source PubMed
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39804528 | Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/39804528 | PubMed |
| 39770405 | Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39770405 | PubMed |
| 38656630 | Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis. | Ann Nucl Med | 2024 | https://conductscience.org/library/papers/38656630 | PubMed |
| 37445504 | Hybrid Molecules of Benzylguanidine and the Alkylating Group of Melphalan: Synthesis and Effects on Neuroblastoma Cells. | J Clin Med | 2023 | https://conductscience.org/library/papers/37445504 | PubMed |
| 37376181 | Clinical Advances and Perspectives in Targeted Radionuclide Therapy. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37376181 | PubMed |
| 37145019 | Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options. | Cancer Med | 2023 | https://conductscience.org/library/papers/37145019 | PubMed |
| 32549040 | MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders. | Front Med (Lausanne) | 2020 | https://conductscience.org/library/papers/32549040 | PubMed |
| 31380451 | Prediction of ong-term ardiac vents by 123I-meta-odobenzylguanidine maging after acute yocardial nfarction and eperfusion herapy. | Asia Ocean J Nucl Med Biol | 2019 | https://conductscience.org/library/papers/31380451 | PubMed |
| 31330766 | Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31330766 | PubMed |
| 31110198 | A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. | Sci Rep | 2019 | https://conductscience.org/library/papers/31110198 | PubMed |
| 28974600 | Molecular radiotheranostics for neuroendocrine tumours. | Clin Med (Lond) | 2017 | https://conductscience.org/library/papers/28974600 | PubMed |
| 28864611 | Norepinephrine Transporter as a Target for Imaging and Therapy. | J Nucl Med | 2017 | https://conductscience.org/library/papers/28864611 | PubMed |
| 25975946 | Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature. | J Nucl Cardiol | 2015 | https://conductscience.org/library/papers/25975946 | PubMed |
| 24523752 | A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG). | Iran J Pharm Res | 2013 | https://conductscience.org/library/papers/24523752 | PubMed |
| 23674235 | Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. | Curr Oncol Rep | 2013 | https://conductscience.org/library/papers/23674235 | PubMed |
| 22628250 | Molecular imaging of adrenal neoplasms. | J Surg Oncol | 2012 | https://conductscience.org/library/papers/22628250 | PubMed |
| 22231492 | Aberrant I-123 MIBG uptake in a gastrointestinal stromal tumour. | Updates Surg | 2013 | https://conductscience.org/library/papers/22231492 | PubMed |
| 21167384 | Molecular imaging of neuroendocrine tumors. | Semin Oncol | 2010 | https://conductscience.org/library/papers/21167384 | PubMed |
| 20307711 | Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. | Pediatr Clin North Am | 2010 | https://conductscience.org/library/papers/20307711 | PubMed |
| 20016892 | Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. | Eur J Nucl Med Mol Imaging | 2010 | https://conductscience.org/library/papers/20016892 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/430189
GET https://conductscience.org/api/papers/v1/430189/cited_by?page=2